Difference between revisions of "Tegafur, gimeracil, oteracil (S-1)"
m (→Also known as) |
m |
||
Line 1: | Line 1: | ||
− | ''Note: this drug is approved in Japan and Europe but not the US | + | ''Note: this drug is approved in Japan and Europe but not the US.'' |
=Mechanism of action= | =Mechanism of action= | ||
Line 8: | Line 8: | ||
*[[Cholangiocarcinoma]] | *[[Cholangiocarcinoma]] | ||
*[[Colon cancer]] | *[[Colon cancer]] | ||
+ | *[[Gallbladder cancer]] | ||
*[[Gastric cancer]] | *[[Gastric cancer]] | ||
*[[Non-small cell lung cancer]] | *[[Non-small cell lung cancer]] | ||
Line 29: | Line 30: | ||
[[Category:Cholangiocarcinoma medications]] | [[Category:Cholangiocarcinoma medications]] | ||
[[Category:Colon cancer medications]] | [[Category:Colon cancer medications]] | ||
+ | [[Category:Gallbladder cancer medications]] | ||
[[Category:Gastric cancer medications]] | [[Category:Gastric cancer medications]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] |
Revision as of 13:46, 1 May 2022
Note: this drug is approved in Japan and Europe but not the US.
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable fluoropyrimidine antagonist composed of tegafur combined with two modulators of 5-flurouracil (5-FU) activity, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, in a molar ratio of 1:0.4:1. Tegafur is a prodrug of 5-fluorouracil, an antimetabolite that inhibits thymidylate synthase, DNA synthesis and cell division, and competes with uridine triphosphate, thus inhibiting RNA and protein synthesis. CDHP is a reversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. Potassium oxonate preferentially localizes in the gut and inhibits the enzyme orotate phosphoribosyl-transferase (OPRT), thereby decreasing activation of 5-FU in the gut and activated 5-FU-related gastrointestinal toxicity.
Diseases for which it is used
- Breast cancer
- Cholangiocarcinoma
- Colon cancer
- Gallbladder cancer
- Gastric cancer
- Non-small cell lung cancer
- Pancreatic cancer
- Rectal cancer
History of changes in EMA indication
- 3/14/2011: Initial marketing authorization as Teysuno.
Also known as
- Code name: S-1
- Brand name: Teysuno, TS-One
- Drugs
- Combination drugs
- Oral medications
- Fluoropyrimidines
- Breast cancer medications
- Cholangiocarcinoma medications
- Colon cancer medications
- Gallbladder cancer medications
- Gastric cancer medications
- Non-small cell lung cancer medications
- Pancreatic cancer medications
- Rectal cancer medications
- EMA approved in 2011
- PMDA approved drugs